| Document Date: 2014-11-03 11:26:18
Open Document File Size: 88,25 KBShare Result on Facebook
City Osaka / Florham Park / / Company The Shionogi-ViiV Healthcare LLC / GlaxoSmithKline / Pfizer Inc. / HIV/AIDS / Shionogi & Co. Ltd. / ViiV Healthcare Ltd. / Financial review / Shionogi Inc. / / Country Japan / United Kingdom / / Event FDA Phase / Business Partnership / / IndustryTerm pharmaceuticals / treatment of HIV / HIV therapy / pharmaceutical / healthcare / / MedicalCondition cancer / HIV / chronic / allergy / AIDS / Infectious Diseases / infection / / Person Tsutae "Den" Nagata / John Pottage / Sally Ferguson / Camilla Bull / / / Position Analyst / forward / Officer / Chief / / Product efavirenz / abacavir / lamivudine / Atripla / Epzicom / HIV-1 / SPRING-2 / / ProvinceOrState New Jersey / / URL www.shionogi.co.jp / www.shionogi.com / www.viivhealthcare.com / /
SocialTag |
Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV London, United Kingdom, 11 July 2012: Shionogi-ViiV Healthcare LLC today announced that initia